The BOIRON Laboratories have acquired from the Swiss company ALKANTIS the trademarks and patents relating to its medical device for analgesic, anti-inflammatory and anti-oedematous purposes called ALKANTIS (ICE STERILE), which consists of a sterile compress with cooling effect.
The price of said acquisition financed with own funds amounts 2,495,000 euros. This price can be completed as follows:
- in 2023, if the net turnover generated by the sales of the product in 2022 exceeds 10 million euros, the additional price will be equal to 10% of the said net turnover beyond 10 million euros. This amount will be capped at 2 million euros;
- in 2028, if the net turnover generated by the sales of the product in 2027 exceeds 20 million euros, the additional price will be equal to 10% of the said net turnover beyond 20 million euros. This amount will be capped at 4 million euros.
Our next update:
January 25, 2018: at market close, publication of the sales revenue for the year 2017.
Person responsible for FINANCIAL information: Christian Boiron
Contact for financial information: Véronique Bouscayrol
Investor relations: +33 (0) 18.104.22.168.43 - e-mail : firstname.lastname@example.org
ISIN Code: FR0000061129 (BOI) - Bloomberg: BOI FP - Reuters: BOIR.PA
The group's financial information and the glossary are online at: www.boironfinance.com